Current Issue: July 2025

First-line Use of Antiangiogenic Agents in Unresectable Hepatocellular Carcinoma: A Double-Edged Sword?

Abstract: Treatment options for hepatocellular carcinoma (HCC), the most prevalent primary liver malignancy, have historically been limited, particularly in unresectable cases with underlying cirrhosis. Initial systemic […]

Revolutionizing Breast Cancer Treatment: The Promise of Antibody-Drug Conjugates

Abstract: Antibody-drug conjugates (ADCs) have significantly advanced the treatment of breast cancer by integrating the specificity of monoclonal antibodies with the cytotoxic efficacy of chemotherapy, thereby […]

Highlights in Upper Gastrointestinal Cancer

From the 2025 American Society of Clinical Oncology Annual Meeting May 30-June 3, 2025 • Chicago, Illinois Addition of Durvalumab to Chemotherapy Improves Event-Free Survival in […]

Sequencing Antibody-Drug Conjugates in Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

H&O  How do you determine whether breast cancer is endocrine-resistant? JC  An endocrine-sensitive patient is someone who has never received or has gone at least a […]

The Addition of Darolutamide to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer

H&O  What was the impetus for the ARANOTE trial? FS  The ARANOTE trial1 was a follow-up to 2 other large phase 3 studies that looked at […]

Is Doublet Therapy Becoming a Standard of Care in Myelofibrosis?

H&O  When is doublet therapy used in myelofibrosis?  RR  Single-agent Janus kinase (JAK) inhibitors are the mainstay of therapy in myelofibrosis, and a total of 4 […]

Reducing Drug Toxicity and Costs Through Off-Label Dosing

H&O  What is wrong with the way doses are currently determined for oncology drugs? MR  The US Food and Drug Administration (FDA) has approved many oncology […]

View More Issues